Figure 1.
Host factors such as physiology and lifestyle, tumor factors that promote lipid dysregulation, and nuances of cancer therapeutics likely influence dyslipidemia in cancer. Dyslipidemia in cancer is likely due to host physiology and lifestyle, tumor processes that promote lipid dysregulation, and effects of cancer therapeutics on key points of lipid metabolism. CHIP, Clonal hematopoiesis of indeterminate potential; LXR-alpha, Liver X receptor alpha; PPAR-gamma, Peroxisome-proliferator activated receptor gamma; LDL, Low density lipoprotein; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; ABCA-1, Adenosine triphosphate binding cassette subfamily A member 1; Created using Biorender.com.